The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.
Commentary|Videos|April 15, 2024
Dr. Goswami's Oncology Journey: Patient-centric Science and Mentorship Stories
Author(s)Sangeeta Goswami, MD, PhD
Sangeeta Goswami, MD, PhD, discusses her career focused in genitourinary cancers, with a focus on patient-centric science and shares mentorship stories along the way.
Advertisement
Sangeeta Goswami, MD, PhD, discusses her career focused in genitourinary cancers, with a focus on patient-centric science and shares mentorship stories along the way.
Advertisement
Related to this article
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA has approved selpercatinib for RET fusion–positive advanced solid tumors.
Advertisement
Advertisement
Trending on OncLive
1
Docetaxel Remains Unbeaten in Immunotherapy-Refractory NSCLC
2
Ris-Rez Meets Phase 3 Efficacy End Point for R/R Osteosarcoma
3
Long-Term Data Refine the Role of Immunotherapy Across Early-Stage NSCLC Settings
4
Cretostimogene Grenadenorepvec Elicits Durable Complete Responses and Bladder Preservation in BCG-Unresponsive NMIBC
5